A detailed history of Black Rock Inc. transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,344,876 shares of AQST stock, worth $3.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,344,876
Previous 478,019 181.34%
Holding current value
$3.11 Million
Previous $965,000 493.68%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.01 - $6.09 $1.74 Million - $5.28 Million
866,857 Added 181.34%
1,344,876 $5.73 Million
Q4 2023

Feb 13, 2024

SELL
$1.29 - $2.47 $2,514 - $4,814
-1,949 Reduced 0.41%
478,019 $965,000
Q3 2023

Nov 13, 2023

BUY
$1.5 - $2.24 $110,499 - $165,011
73,666 Added 18.13%
479,968 $734,000
Q2 2023

Aug 11, 2023

BUY
$1.06 - $2.49 $49,442 - $116,143
46,644 Added 12.97%
406,302 $670,000
Q1 2023

May 12, 2023

BUY
$0.72 - $1.15 $1,398 - $2,234
1,943 Added 0.54%
359,658 $410,000
Q4 2022

Feb 13, 2023

SELL
$0.77 - $1.05 $12,445 - $16,971
-16,163 Reduced 4.32%
357,715 $321,000
Q3 2022

Nov 14, 2022

BUY
$0.63 - $1.73 $1,362 - $3,740
2,162 Added 0.58%
373,878 $437,000
Q2 2022

Aug 12, 2022

SELL
$0.64 - $2.57 $3,072 - $12,338
-4,801 Reduced 1.28%
371,716 $237,000
Q1 2022

May 12, 2022

BUY
$2.28 - $4.26 $64,184 - $119,923
28,151 Added 8.08%
376,517 $983,000
Q4 2021

Feb 10, 2022

BUY
$3.69 - $6.37 $64,279 - $110,965
17,420 Added 5.26%
348,366 $1.35 Million
Q3 2021

Nov 09, 2021

SELL
$3.25 - $4.66 $65,221 - $93,516
-20,068 Reduced 5.72%
330,946 $1.44 Million
Q2 2021

Aug 11, 2021

BUY
$3.29 - $5.21 $1.15 Million - $1.83 Million
351,014 New
351,014 $1.39 Million

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $123M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.